This segment focuses on the discovery and development of targeted therapeutics for various cancers, utilizing a precision medicine approach. Research and development activities include identifying and validating drug targets, designing and synthesizing small molecule inhibitors and other therapeutic modalities, and conducting preclinical and clinical trials. Technologies employed include synthetic lethality, molecular diagnostics, and advanced medicinal chemistry. The primary therapeutic areas are solid tumors with specific genetic mutations or molecular signatures, such as those with MTAP deletions or GNAQ/GNA11 mutations. The goal is to improve patient outcomes by providing treatments tailored to their specific cancer profiles. Market positioning is based on being a leader in synthetic lethality and precision medicine, with competitive advantages in its pipeline of first-in-class drug candidates and strategic partnerships. Future opportunities include expanding the pipeline, securing regulatory approvals, and commercializing approved therapies. Clinical trials and regulatory aspects are critical, with a focus on FDA approval and compliance. Partnerships with companies like Pfizer and GlaxoSmithKline are key to advancing clinical programs.

This segment encompasses the clinical development of IDEAYA's lead product candidates and preclinical programs. The primary focus is on conducting Phase I/II clinical trials for IDE397 (MAT2A inhibitor) and IDE196 (PKC inhibitor), as well as advancing preclinical programs targeting PARG, Pol Theta, and WRN. Research and development activities include designing and executing clinical trials, analyzing clinical data, and preparing regulatory submissions. Technologies used include molecular diagnostics for patient selection, advanced clinical trial design, and biomarker analysis. The therapeutic areas covered include solid tumors, uveal melanoma, skin melanoma, and genetically defined cancers. The patient impact is aimed at providing effective treatments for patients with limited therapeutic options. Market positioning is based on the development of innovative therapies for unmet medical needs. Future opportunities include expanding clinical trial programs, securing regulatory approvals, and commercializing approved therapies. Regulatory and clinical aspects are critical, with a focus on FDA approval and compliance. Collaborations with partners like Pfizer and Cancer Research UK are essential for advancing clinical programs and expanding the pipeline.